1. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) 
Byoung Chul Cho, MD, PhD, Dong-Wan Kim, MD, PhD, Alessandra Bearz, MD, Scott A. Laurie, MD, FRCPC, Mark McKeage, MBChB, PhD, FRACP, Gloria Borra, MD, Keunchil Park, MD, PhD, Sang-We Kim, MD, Marwan Ghosn, MD, MHHM, Andrea Ardizzoni, MD, Evaristo Maiello, MD, Alastair Greystoke, MD, PhD, Richard Yu, BS, Karen Osborne, BSc, Wen Gu, PhD, Jeffrey W. Scott, BSc, Vanessa Q. Passos, MD, PhD, Yvonne Y. Lau, PhD, Anna Wrona, MD 
Journal of Thoracic Oncology 
Volume 12, Issue 9, Pages (September 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1 CONSORT trial flow diagram. PK, pharmacokinetics.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Steady-state pharmacokinetics on cycle 2 day 1 (pharmacokinetics analysis set–steady state [n = 97]).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions